TyRx Pharma, Inc. Announces the Appointment of Gary Young, PharmD, MBA as Vice President, Marketing

MONMOUTH JUNCTION, NJ, Mar 31 (MARKET WIRE) --
TyRx Pharma, Inc., a leader in the commercialization of implantable
medical-pharmaceutical devices, today announced that it has appointed Gary
Young as Vice President, Marketing.

"Gary brings over 25 years' experience in building successful medical device
product commercial launches to TyRx and we are excited to have him join our
team," remarked William Edelman, President and CEO for TyRx. Mr. Edelman
continued, "Gary's tremendous depth and experience will enable our strategy
in the implantable medical-pharmaceutical device sector as TyRx moves from the
development stage to a full commercial footing. In January, we announced FDA
clearance of the AIGISrx(TM) CRMD Anti-Bacterial Envelope, our third implantable
combination drug-device product to reach the market. The funds from our recently
announced financing round in February will enable our continuing transition
from the development stage to commercialization, targeting the market in
medical device infection control estimated at $3 billion in the United States."

Mr. Young has over 25 years of increasing leadership positions within the
cardiovascular device industry, with emphasis being within cardiac
surgery,implantable pacemakers and heart valves. He has held senior level
sales and
marketing positions moving from sales representative to Vice President, Sales
and
Marketing for organizations such as Medtronic, Pacesetter/St Jude, Sulzer
Carbomedics
and Edwards Lifesciences. While at Medtronic, Mr. Young was nominated for the
Malcolm Baldridge Quality Award and launched the world's mostly widely
prescribed
single, chamber rate responsive pacemaker generating $144.3 million annual
revenue
1st year post launch. Mr. Young has launched over 40 life science technology
products, has extensive global experience and has developed and executed
global sales and marketing strategies for some of the world's most successful
device companies.

Mr. Young remarked, "I am very excited in having the opportunity to join a
group of industry leaders bringing a much needed technology to the market.
This is an exciting time for both TyRx and the market. TyRx brings a robust and
unique combination of pharmaceuticals and medical devices designed to enhance
patient therapy, increase physician productivity while addressing the ever
increasing cost of healthcare."

This notice follows TyRx's February 27th announcement that the Company
raised $25
million in a venture capital financing led by Clarus Ventures and co-led by
Pappas
Ventures.

About AIGISrx(TM) CRMD

More than 400,000 cardiac rhythm management devices (CRMDs) are implanted
each year
in the U.S. According to a recent study presented during the Heart Rhythm
Society Heart Rhythm 2006 Scientific Sessions (Boston), the University of
Pittsburgh Medical Center noted that the 2003 national incidence of CRMD implant
infection was estimated to be 5.8% for pacemakers and 3.7% for implantable
cardioverter defibrillators (ICDs). Furthermore, according to Infection Control
Today
(8/2003), the average cost of each infection related to invasive medical
devices varies from $34,000 to $56,000. TyRx Pharma's AIGISrx(TM) CRMD
Anti-Bacterial Envelope contains the antimicrobial agents, rifampin and
minocycline, which have been shown to reduce infection by organisms
representing a majority of the infections reported in CRMD-related endocarditis,
including MRSA (methicillin-resistant Staphylococcus aureus). In addition, it
is intended to securely hold a pacemaker or ICD in order to create a stable
environmentwhen implanted in the body. This device is only intended to be used
in
conjunction with pacemakers and ICDs.

AIGISrx(TM) CRMD is constructed of knitted filaments of polypropylene coated
with a
proprietary resorbable polymer that elutes the antimicrobial agents for a
minimum of
seven days to reduce the risk of infection of the implanted CRMD following
surgery. In in vitro and in vivo studies, AIGISrx(TM) CRMD demonstrated
antimicrobial activity against Methicillin Resistant Staphylococcus aureus
(MRSA),
Staphylococcus aureus, Staphylococcus epidermidis, Acinetobacter baumanii,
Enterobacter aerogenes and Proteus mirabilis, which represent a majority of the
infectionsreported in CRMD-related endocarditis. It should be noted that the in
vitroand in vivo activity of the AIGISrx(TM) CRMD antimicrobials is variable
against
non-epidermidis strains of coagulase-negative staphylococci. The company
plans to launch AIGISrx CRMD in the US beginning in April 2008.

About TyRx Pharma, Inc.

TyRx Pharma, Inc., an ISO 9001:2000 and ISO 13485:2003 certified medical
device
manufacturer, commercializes implantable combination drug-device products
utilizing
novel biomaterials, including technology licensed exclusively from Rutgers, The
State University of New Jersey. Additionally, TyRx has exclusively licensed from
Baylor
College of Medicine and The University of Texas M. D. Anderson Cancer Center
product patents and associated technologies to address the problem of post
surgical nosocomial infection. TyRx is deploying its capabilities across a broad
range of combination implantable medical-pharmaceutical devices. The
combinationproducts sector (products incorporating both a drug & a device
component) is
expected to be the highest growth segment of the medical products industry and
TyRx is positioned to be an innovative applications leader in the space.

For more information, please visit www.tyrxpharma.com.

Contact:

Bill Edelman
CEO
TyRx Pharma, Inc.
Office: 732-246-8676
Direct: 732-964-1101
Cell: 617-759-5451
Email Contact

Copyright 2008, Market Wire, All rights reserved.

-0-